Vaxart was served a grand ju­ry sub­poe­na in Ju­ly over its con­tro­ver­sial role in OWS-fund­ed pre­clin­i­cal study

One-time pen­ny stock play­er Vaxart made mar­ket waves Tues­day morn­ing when the com­pa­ny an­nounced it had dosed the first pa­tients in the Phase I study for its oral Covid-19 vac­cine can­di­date. But un­der­neath those head­lines came an­oth­er piece of news: a grand ju­ry sub­poe­na.

In an 8-K fil­ing with the SEC on Wednes­day, Vaxart re­vealed the US At­tor­ney’s Of­fice for the North­ern Dis­trict of Cal­i­for­nia served the com­pa­ny with the sub­poe­na back in Ju­ly. The gov­ern­ment is prob­ing Vaxart’s par­tic­i­pa­tion in a study fund­ed by Op­er­a­tion Warp Speed and the com­pa­ny’s dis­clo­sure of the news, as well as grants, war­rant trans­ac­tions, and oth­er fi­nanc­ing mat­ters be­gin­ning in March 2020, ac­cord­ing to the fil­ing.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER